

Day 1 | Wednesday 23 October

08:45 ● **Welcoming remarks**, with *Alexis Goosdeel* and *João Goulão* 📍 Main stage

Plenary I: New frontiers for addiction science

Chair: *Antoni Gual*

● Introducing Lisbon Addictions 2019: The future is here, it's just not evenly distributed yet, *Paul Griffiths*

09:00 Future perspectives on the positive and negative effects of cannabinoids and health, *Marilyn Huestis* 📍 Main stage

● Does Cognitive Bias Modification help in the treatment of addictive behaviours? 📍 F1

● (09:30 to 11:00) REMOTE digital monitoring for risk of relapse – FuturiZe test-drive experience 📍 F2

10:30 NETWORKING ZONE

- | | | |
|---|---|---|
| ● Focus on the EU borders 📍 C3 | ● Understanding and improving health and social outcomes 📍 N3 | ● Depot medications for unmet treatment needs in opioid use disorder 📍 N2 |
| ● Innovative methods for exploring new drug-related trends 📍 I4 | ● Cannabis beyond psychosis 📍 C1 | ● Stimulants — use, harm and interventions 📍 N4 |
| ● Development of a core outcome set for treatment of substance use and addictive behaviour disorders 📍 F3 | ● Alcohol: epidemiology and adolescence 📍 C2 | ● Addiction in a digital world – FuturiZe thought leader round table 📍 F1 |
| ● Emerging issues in the study of behavioural addictions 📍 I3 | ● Opioid-related deaths in Europe and Australia 📍 Main stage | ● Challenges for harm reduction I 📍 I2 |
| | ● Definition of disorders 📍 N1 | ● Analysis and monitoring of ongoing darknet drug purchases – FuturiZe discussion and demo 📍 F2 |
| | ● Insights in biology 📍 I1 | |

12:20 NETWORKING ZONE

- | | | |
|--|--|---|
| ● 2009-2019 — A crucial decade in international drug policy 📍 C2 | ● European Research Area Network on Illicit Drugs 📍 I4 | ● Digital health multi-sector co-ideation game jam 📍 F2 |
| ● Nicotine harm reduction 📍 N4 | ● Improving the validity of drug-related deaths data for policy making 📍 C1 | ● Speculative Addictions I 📍 F1 |
| ● A global network of universities as the future of addiction education 📍 I1 | ● Alcohol-related brain damage and its relation to deshabilitation treatment response 📍 I3 | ● Treatment — challenges, determinants and responses 📍 N3 |
| ● The future of hepatitis C among people who inject drugs 📍 Main stage | ● Improving delivery of healthcare programmes 📍 C3 | ● Modelling the impact of decriminalisation 📍 N1 |
| | ● Risk behaviours in context 📍 N2 | ● The challenges of monitoring new drugs 📍 I2 |

14:50 Break

- | | | |
|---|---|---|
| ● Enhancing the role of drug treatment services for HCV elimination among people who inject drugs 📍 C1 | ● New clinical profiles in gambling disorder in Europe 📍 C2 | ● Modernisation, stagnation or roll-back 📍 N4 |
| ● Progress in alcohol research and treatment 📍 Main stage | ● Implementation of supervised drug consumption facilities in Zurich: a success story 📍 N2 | ● New psychoactive substances 📍 N3 |
| ● Needs-based planning for substance use treatment systems: The new generation of principles, methods and models 📍 I4 | ● Drug policy and human rights 📍 I1 | ● Innovative communication – FuturiZe thought leader round table 📍 F1 |
| ● Epidemiology of hepatitis C among people who use drugs — data to inform future planning 📍 I3 | ● Improving responses to opioid-related harm 📍 C3 | ● Prevention strategies 📍 I2 |
| | ● Virtual Reality (VR) facilitated cue exposure to reduce craving – FuturiZe discussion and demo 📍 F2 | ● Therapeutic horizons I 📍 N1 |
| | | ● Improving youth OUD treatment through family engagement and assertive outreach 📍 F3 |

16:30 NETWORKING ZONE

- | | | |
|---|---|---|
| ● Migration, drug use and treatment 📍 I2 | ● Alcohol: short communications on policy and treatment 📍 N3 | ● An epidemiological overview of new psychoactive substances use in Europe 📍 C3 |
| ● Gender and drugs in Europe 📍 N1 | ● Harm reduction across addictions: recent results and future directions 📍 I3 | ● My virtual reality in counselling: digital reading & writing in text-based online-addiction-counselling 📍 F3 |
| ● Closing the gaps: HIV and Hepatitis continuums of care with a focus on people who inject drugs 📍 C1 | ● Big data and innovative monitoring – FuturiZe thought leader round table 📍 F1 | ● Developing tools for monitoring of drug policy and practice from the view point of civil society organisations in Europe 📍 I1 |
| ● Digital health multi-sector co-ideation game jam 📍 F2 | ● Extending the evidence-base of opioid substitution treatment 📍 I4 | ● Nicotine harm reduction: opportunities and challenges 📍 Main stage |
| ● Theoretical and epidemiological considerations in gambling and other behavioural addictions 📍 C2 | ● Getting your addiction research published 📍 N4 | |
| ● Responding to vulnerability and special needs 📍 N2 | | |

18:20 Break

- | | | |
|---|--|--|
| ● Workforce development and training 📍 N3 | ● Social robots as motivational interviewers – FuturiZe discussion and demo 📍 N4 | ● Consumption rooms: overcoming implementation challenges 📍 I4 |
| ● Innovative approaches for assessing or impacting demand for substances 📍 C1 | ● Smoking and health 📍 I1 | ● Treatment in the justice system 📍 C2 |

Big debate: Will changes in cannabis policy result in greater costs or greater benefits?

Moderator: *Florence Ranson*

Panel: *Laura d'Arrigo, Jennifer Price, Robin Murray, Wayne Hall and Tom Blickman*

📍 Main stage

19:30 ● **Welcome cocktail** NETWORKING ZONE

COMPLETE PROGRAMME



Day 2 | Thursday 24 October

Plenary II: Learning from the past to meet the challenges of the future

Chair: *Eilish Gilvarry*

- 09:00 **Future perspectives for reducing tobacco related harm – what have we learnt?, Karl Lund** Main stage
The future of prevention science, *Johanna Gripenberg*
- Cannabis and causality — using multiple methods to unpick links between cannabis and neurobiology, cognition and mental health** F3

10:30 NETWORKING ZONE

- Towards a consensus approach to opioid substitution treatment outcomes and how they are monitored** N1
- Drug-related interventions in European prisons** I3
- Understanding behaviours, risks and harms** N3
- Candidates of behavioural addictions** I2
- Monitoring trends and developments** I1
- Methods and approaches to inform drug policy and practice** N4
- Individually-tailored support and education for safer injection** N2
- Building a professional workforce for drug demand reduction** I4
- Funding opportunities for early career/experienced researchers** F3
- The European Mosaic: prescription drug misuse across borders** C1
- Understanding pathways to stimulant use: a mixed methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe** C2
- Lancet review series: Using evidence to better respond to drug problems - a call for action** Main stage
- Gender perspectives** C3

12:20 NETWORKING ZONE

- Post-marketing prescription drug mosaic surveillance** Main stage
- Added to work: the use of cognitive enhancers in the workplace and the implications for occupational safety and health** F2
- Alcohol: harms and policies** F3
- Infusing policy with evidence** C3
- Reducing drug-related deaths** C2
- Regulating the low-THC cannabis market in Europe** F1
- Cannabis — risks and responses** N4
- Enhancing hepatitis C treatment outcomes among people who use drugs** I1
- Opioid-related deaths: learning from pharmacology, laboratory-based studies and physical assessments** C1
- Treatment adherence** I4
- (12:40 to 13:20) FuturiZe technology tours** F2
- How to inform policy and decision makers about evidence-based prevention** N2
- Injecting, risk and reducing harm** N3
- Focus on prescription drugs I** I3
- Policy and treatment** I2
- Using new technology and innovative methods to measure substance use and related harm** N1

14:50 Break

- Global changes in cannabis products** Main stage
- Future addictions project game jam** F3
- Emerging issues in the management of conflicts of interest** I1
- Alcohol: comorbidity, risk and consequences** C3
- Safer drugs? – FuturiZe thought leader round table** F1
- The cannabis policy kaleidoscope** C2
- Problematic usage of Internet: from assessment to intervention** C1
- Take-home naloxone — its role in preventing opioid-related deaths in Europe** I3
- Drug markets** I4
- Exploring comorbidities in addiction** I2
- Insight into the dynamics of substance use (research) in nightlife settings** N1
- Treatment interventions** N3
- Youth pathways** N2
- Transcranial Magnetic Stimulation (TMS) – FuturiZe discussion and demo** F2

16:30 NETWORKING ZONE

- Prison and drugs in Europe** F3
- European Drug Emergency Network Plus (Euro-DEN Plus)** Main stage
- Factors influencing recovery** I3
- How to support the implementation of a comprehensive policy for alcohol, narcotics, doping, and tobacco from a public health perspective** I1
- New methods** C2
- New perspectives on cannabis use disorders and their treatment** I4
- Focus on the EU borders** I2
- Alcohol policies and preventions** C1
- Gambling research** N1
- Methods and measurement of economic cost of substance use** C3
- Recovery from problematic drug use** N2
- Emerging health needs amongst adolescents who regularly use alcohol, cannabis or tobacco** F2
- Alcohol: short communications on basic science, adolescence and comorbidity** N3
- Issues for cannabis policy** N4
- Striving towards the future elimination of Hep C among people who use drugs** F1

18:20 Break

- Software-automated approach to monitoring online e-shops offering new psychoactive substances** F3
- Developing new prevention strategies to improve the situation of clients and employees of harm reduction services** N2
- Drug-checking technology – FuturiZe discussion and demo** F2
- Nightlife, festivals and other recreational settings** N3
- Measuring and monitoring drug policy for research, surveillance and practice** N1
- Opioids — current and emerging lessons** N4
- Speculative addictions II** F1
- Cannabis labelling and health warnings: use and impacts** I4
- Challenges for harm reduction II** I3
- Prevention science and measurement of demand reduction quality standards** C1
- Electronic cigarettes/vaping devices** I2
- Big debate: Industry friend of foe? Can industry contribute to better addiction science, policy, and actions?** Main stage
Moderator: *Florence Ranson* Panel: *Henrietta Bowden-Jones, Axel Klein, Niamh Fitzgerald, Paul Wallace and Ian Gilmore*

19:30 Networking buffet dinner NETWORKING ZONE

Programme overview

Day 3 | Friday 25 October

Plenary III: Horizons in addiction science

Chair: *Michael Farrell*

- Implications for the future of our developing understanding of addictive processes and future therapeutic options, *Olivier George*
Future perspectives for new formulations for medications for opioid use disorder: hopes and fears, *Sharon L. Walsh* 📍 Main stage
- 09:00 ● Studying the operation of new forms of cannabis supply 📍 C1
- Illicit drug markets: strategic analysis for a safer Europe 📍 I2
- Treatment of elderly alcohol dependent patients 📍 C2
- Food addiction: a transdiagnostic construct of increasing clinical interest 📍 N1
- Contemporary issues in addictions 📍 C3
- Attentional Bias Modification Training as add-on to regular treatment in alcohol and cannabis use disorder 📍 F1
- REMOTE digital monitoring for risk of relapse – FuturiZe discussion and demo 📍 F2

10:30  NETWORKING ZONE

Big debate: How do we get greater involvement of civil society and affected communities in shaping addiction research, policies and practice?

Moderator: *Florence Ranson*

Panel: *Mariann Skar, Marie Nougier, Tony Duffin and John McCracken*

📍 Main stage

- 10:45 ● Supporting future cannabis policy/achieving a Standard Joint Unit – FuturiZe workshop 📍 F3
- Monitoring drug trends in the EU and Australia using digital and online instruments 📍 F1
- Diversity in behavioural addictions 📍 N1
- The development and implementation of the ADVANCE intervention to reduce intimate partner violence perpetration by men in substance use treatment 📍 C3
- Approaches to support the development of an evaluative culture to promote better drug policy for the future 📍 N2
- Treatment — improving standards and outcomes 📍 N3
- Epidemiology of infectious diseases 📍 I4
- Focus on prescription drugs II 📍 C2
- Young people's addictions treatment 📍 N4
- Drug policy debates: how are routine monitoring data used? 📍 I2
- Alcohol: Alcohol Use Disorder treatment and outreach 📍 I1
- Opioid-related deaths: learning from epidemiological studies 📍 I3
- Therapeutic horizons II 📍 C1

12:15  NETWORKING ZONE

Closing session

Chair: *Julia Sinclair*

- 12:30 ● Preventing deaths from heroin overdose: better science, fuller understanding, greater impact, *Sir John Strang*
Future perspectives on designing information for impact and decision-making, *Angela Morelli* 📍 Main stage

- 13:30 ● Closing remarks, with *Manuel Cardoso* 📍 Main stage

13:45 After this session, lunch boxes will be available

Guided tours 📍 Poster tours room

Day 1 | Wednesday 23 October

- 10:50 ● Progress in alcohol research and responses - EUFAS session 1
- 12:20 ● Measuring drug use to monitor trends in different populations - ISSDP session 1
- 13:20 ● Problematic gaming and digital media use - ISSBA session 1
- 15:00 ● Behavioural addictions: reasons, risks and responses - ISSBA session 2

Day 2 | Thursday 24 October

- 10:50 ● Alcohol perspectives and prevention - EUFAS session 2
- 12:20 ● Making better use of existing data through standardisation, methods and analysis - ISSDP session 2
- 13:20 ● The Reitox network session
- 15:00 ● Opioid-related deaths and other harms: current and emerging lessons - SSA session

Colour code:

- Plenary session
- Big debate
- Structured session
- Workshop
- Poster guided tour
- Oral presentation session
- Short communication session

Disclaimer:

For the most recent version of the programme, go to the lisbonaddictions.eu website and app.

Visit the app and website and fill in the conference survey

